Table 3.
Model-Based Mean Differences (95% CIs) of Pre-ART Biomarker Concentrations for Participants Who Were Starting With Pre-ART Overweight or Obese BMI Versus Normal BMI, Separately by Subsequent Weight Gain on ART
| Weight Gain Subgroup Over 96 Weeks | Pre-ART BMI Category vs Normal Weight | IL-6, log10 pg/mL | sTNF-RII, log10 pg/mL | CXCL-10, log10 pg/mL | sCD163, log10 ng/mL | hsCRP, log10 μg/mL |
|---|---|---|---|---|---|---|
| Maintainers | Overweight | 0.09 (−.01 to .18) | 0.08 (.03 to .13) | 0.06 (−.03 to .14) | 0.08 (.01 to .14) | 0.31 (.14 to .49) |
| Obese | 0.28 (.16 to .40) | 0.17 (.10 to .23) | 0.09 (−.02 to .2) | 0.18 (.10 to .26) | 0.45 (.23 to .67) | |
| Gainers | Overweight | −0.14 (−.22 to −.05) | −0.03 (−.07 to .02) | −0.07 (−.15 to .01) | 0.04 (−.02 to .09) | −0.15 (−.30 to .01) |
| Obese | −0.06 (−.15 to .04) | −0.01 (−.06 to .04) | −.05 (−.14 to .04) | 0.05 (−.02 to .11) | 0.07 (−.11 to .24) |
Models adjusted for sex, age (by decade), race/ethnicity, pre-ART viral load and CD4 cell count, and ART assignment. Bold text indicates a statistically significant comparison.
Abbreviations: ART, antiretroviral therapy; BMI, body mass index; CI, confidence interval; hsCRP, high-sensitivity C-reactive protein; IL-6, interleukin 6; sTNF-RII, soluble TNF-α receptor II.